40,624 Shares in ICON Public Limited (NASDAQ:ICLR) Bought by Foyston Gordon & Payne Inc

Foyston Gordon & Payne Inc bought a new stake in ICON Public Limited (NASDAQ:ICLR) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 40,624 shares of the medical research company’s stock, valued at approximately $11,672,000. ICON Public comprises approximately 2.9% of Foyston Gordon & Payne Inc’s investment portfolio, making the stock its 11th biggest position.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Icon Wealth Advisors LLC lifted its holdings in shares of ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after purchasing an additional 11,840 shares during the period. First Horizon Advisors Inc. boosted its holdings in ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 151 shares during the last quarter. Arkadios Wealth Advisors boosted its position in ICON Public by 5.0% during the third quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock valued at $371,000 after acquiring an additional 62 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its position in shares of ICON Public by 23.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after acquiring an additional 96 shares in the last quarter. Finally, Whittier Trust Co. lifted its stake in shares of ICON Public by 12.3% in the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock valued at $1,155,000 after purchasing an additional 441 shares during the period. 95.61% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ICLR. Barclays lowered their target price on ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Truist Financial lowered their price objective on shares of ICON Public from $363.00 to $295.00 and set a “buy” rating for the company in a research note on Monday, October 28th. The Goldman Sachs Group cut their target price on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Robert W. Baird decreased their price target on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research note on Wednesday, November 20th. Finally, Redburn Atlantic started coverage on shares of ICON Public in a research report on Monday, October 14th. They set a “neutral” rating and a $311.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $292.45.

ICON Public Trading Up 0.8 %

NASDAQ ICLR opened at $219.23 on Tuesday. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The business has a fifty day simple moving average of $240.36 and a 200 day simple moving average of $289.58. ICON Public Limited has a 12 month low of $183.38 and a 12 month high of $347.72. The firm has a market capitalization of $18.09 billion, a P/E ratio of 24.44, a PEG ratio of 1.61 and a beta of 1.21.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the prior year, the company earned $3.10 EPS. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, analysts predict that ICON Public Limited will post 13.42 EPS for the current fiscal year.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.